Formed in March 2020 by Dr Ji Eun Lee, MediMab Biotherapeutics Ltd is a subsidiary of MediMabBio, Inc., a South Korea-based biotechnology firm founded by an Oxford graduate. MediMabBio’s discovery platform utilises systems biology to identify significantly improved first-in-class immuno-oncology drugs that can actively target a range of advanced and solid tumours. The company has developed 4 product pipelines of highly promising novel drugs that aim to overcome the current limitations of cancer immunotherapy.
Having raised $3M for pre-series A funding last year, MediMabBio is expected to raise a further $16M next month in Series A funds.
Dr Li Eun Lee commented "The reason we have chosen the BioEscalator as our base is because we believe that it would be a perfect environment for our company to start and grow within the UK. It provides an excellent environment in terms of growth, flexibility and accessibility to world-class local facilities that are already in place. Its location is also advantageous for us to interact and collaborate with other leading scientists based in the university, and other related communities and hospitals. We also appreciate the support we receive from the BioEscalator staff and colleagues."